Estimate of the cost of multiple sclerosis in Spain by literature review

Expert Rev Pharmacoecon Outcomes Res. 2017 Aug;17(4):321-333. doi: 10.1080/14737167.2017.1358617. Epub 2017 Jul 28.

Abstract

Multiple Sclerosis (MS) is a progressive disease leading to increasing disability and costs. A literature review was carried out to identify MS costs and to estimate its economic burden in Spain. Areas Covered: The public electronic databases PubMed, ScienceDirect and IBECS were consulted and a manual review of communications presented at related congresses was carried out. A total of 225 references were obtained, of which 43 were finally included in the study. Expert Commentary: Three major cost groups were identified: direct healthcare costs, direct non-healthcare costs and indirect costs. There is a direct relationship between disease progression and increased costs, mainly direct non-healthcare costs (greater need for informal care) and indirect costs (greater loss of productivity). The total cost associated with MS in Spain is €1,395 million per year, and that the mean annual cost per patient is €30,050. Beyond costs, a large impact on the quality of life of patients, with an annual loss of up to 13,000 quality-adjusted life years was also estimated. MS has a large economic impact on Spanish society and a significant impact on the quality of life of patients.

Keywords: Cost of the disease; Spain; literature review; multiple sclerosis.

Publication types

  • Review

MeSH terms

  • Cost of Illness*
  • Disease Progression
  • Health Care Costs*
  • Humans
  • Multiple Sclerosis / economics*
  • Multiple Sclerosis / physiopathology
  • Multiple Sclerosis / therapy
  • Quality of Life
  • Quality-Adjusted Life Years
  • Spain